




1642

PATENT

D#15

I hereby certify that on March 18, 2002, which is the date I am signing this certificate, I am depositing this correspondence the United States Postal Service, first class mail, in an envelope addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231


Florence Thys-Dorpet

Applicant: Schor et al.

Serial No.: 09/581,651

Filed: June 15, 2000

Title: Polypeptides, Polynucleotides and Uses Thereof

Examiner: Steven L. Rawlings

Group Art Unit: 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

APR 01 2002

INFORMATION DISCLOSURE STATEMENT

TECH CENTER 1600/2900

Sir:

Applicant brings the references listed below and on the attached Form PTO-1449 to the examiner's attention. 37 C.F.R. § 1.56. Do not construe the filing of this information disclosure statement as a representation that applicant has made a search (37 C.F.R. § 1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. We enclose copies of the cited documents.

U.S. Patent Documents

4,980,279	5,300,630
5,049,658	5,571,679
5,124,155	5,629,291

Foreign Patent Documents:

EPO 0 207 751	PCT WO 94/16085
EPO 0 344 134	PCT WO 99/02674
PCT WO 90/00567	


We bring these foreign language documents to the examiner's attention with a concise explanation of the relevance of each document, as the individual designated in 37 C.F.R.

§ 1.56(c) as most knowledgeable about the content of the information of each document presently understands it.

We also enclose 22 relative publications and articles for consideration.

We request that the examiner show that he or she considered the cited references by returning a copy of the attached form PTO-1449 with initials or other appropriate marks, and that the examiner make the references of record as cited references in the application.

March 18, 2002



Guy Porter Smith Reg. No. 20,142
Attorney for Applicant

Oppenheimer Wolff & Donnelly LLP
2029 Century Park East, 38th Floor
Los Angeles, CA 90067-3024
Telephone: (310) 788-5000 • Fax: (310) 788-5100

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 3

Complete if Known

Application Number	09/581,651
Filing Date	June 15, 2000
First Named Inventor	Schor et al.
Art Unit	1642
Examiner Name	Steven L. Rawlings
Attorney Docket Number	350013-72

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	1	US-4,980,279	12/25/90	PETERS et al.
	2	US-5,049,658	09/17/91	KIMIZUKA et al.
	3	US-5,124,155	06/23/92	REICH, Cary
	4	US-5,300,630	04/05/94	MATSUURA et al.
	5	US-5,571,679	11/05/96	SEKIGUCHI et al.
	6	US-5,629,291	05/13/97	RUOSLAHTI et al.

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	7	EPO - 0 207 751	06/27/86	BARELLA, Francisco
	8	EPO - 0 344 134	05/25/89	ZARDI, Luciano
	9	PCT - WO 90/00567	01/25/90	SCHOR et al.
	10	PCT- WO 94/16085	07/21/94	IRANI, Meher
	11	PCT - WO 99/02674	01/21/99	SCHOR, Seth

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/581,6511
		Filing Date	June 15, 2000
		First Named Inventor	Schor et al.
		Group Art Unit	1642
		Examiner Name	Stephen L. Rawlings
Sheet 1 of 3	Attorney Docket Number	350013-72	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	2
	12	KORNBLIHTT, et al., Primary structure of h man fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO Sequence Database Accession No. X0271; 4:1755-1759(1985)	
	13	KORNBLIHTT et al., Primary structure of h man fibronectin: differential splicing may generate at least 10 polypeptides from a single gene, EMBO, (USA) vol. 4 pp. 1755-1759 (1985)	
	14	KORNBLIHTT et al., SWISSPROT Sequence Database Accession No. P02751, (1986)	
	15	PIRI Sequence database (1985) Accession Ref. FNHU	
	16	DEAN et al., Cloning and analysis of the promoter region of the human fibronectin gene; Proc. Natl. Acad. Sci, USA, Vol. 84, pp. 1876-1880, April 1987	
	17	HYNES et al., EMBL Data library PIR2 AccessionNo. S14428, 1989	
	18	DESIMONE et al., Identification and characterization of alternatively spliced fibronectin mRNAs expressed in early Xenopus embryos, SWISSPROT Database Accession Ref. FINC_XENLA, Dev. Biol. vol. 149 pp. 357-369 (1992)	
	19	SCHOR, Fibroblast subpopulations as accelerators of tumor progression: The role of migration stimulating factor, Epithelial-Mesenchymal Interactions in Cancer, 1995 pp. 273-296, Switzerland	
	20	SCHOR et al., Migration stimulating factor (MSF): Its structure mode of action and possible function in health and disease; The Society of Experimental Biology 1993, pp. 235-251, UK	
	21	GREY et al., Purification of the migration stimulating factor produced by fetal and breast cancer patients fibroblasts, Proc. Natl. Acad. Sci, USA, Vol. 86, pp. 2438-2422, April 1989	
	22	SCHOR et al., Fetal-like fibroblasts: their production of migration stimulating factor and role in tumor progression, Mammary Tumorigenesis and Malignant Progression, pp. 277-298, 1994	
	23	IRWIN et al., Inter-and intra-site heterogeneity in the expression of fetal-like phenotypic characteristic by gingival fibroblasts: potential significance for wound healing, Journal of Cell Science, Vol 107, p 1333-1346 (1994) UK	
	24	SCHOR et al., Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma, Int. J. Cancer, Vol. 59, pp. 25-32 (1994)	
	25	PICARDO et al., Migration stimulating activity in serum of breast cancer patients, The Lancet, Vol. 337, pp. 130-134, January 19, 1991	

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/581,6511
		Filing Date	June 15, 2000
		First Named Inventor	Schor et al.
		Group Art Unit	1642
		Examiner Name	Stephen L. Rawlings
Sheet <u> </u> of <u> 3 </u>	Attorney Docket Number		350013-72



RECEIVED
APR 01 2002
TECH CENTER 1600/2900


26	✓	ELLIS et al., Antagonistic effects of TGF-β1 and MSF on fibroblast migration and hyaluronic acid synthesis, Possible implications for dermal wound healing, Journal of Cell Science, Vol. 102, pp. 447-45 (1992) UK	
27	✓	PICARDO et al., Detection of migration stimulating activity in wound fluid, Experimental and Molecular Pathology Vol. 57, pp 8-21 (1992)	
28	✓	SCHOR et al., Heterogeneity amongst fibroblasts in the production of migration stimulating factor (MSF): Implications for cancer pathogenesis, Cell Motility Factors, pp. 127-146, 1992	
29	✓	SCHOR et al., Fibroblasts from cancer patients display a mixture of both fetal and adult-like phenotypic characteristics; Journal of Cell Science, Vol. 90, pp. 401-407 (1988) UK	
30	✓	SCHOR et al., Fetal and cancer patient fibroblasts produce an autocrine migration stimulating factor not made by normal adult cells, Journal of Cell Science, Vol. 90, pp. 391-399 (1988) UK	
31	✓	SCHOR et al., Characterization of migration-stimulating factor (MSF): Evidence of its role in cancer pathogenesis, Cancer Investigation Vol. 8(6), pp. 665-667, (1990)	
32	✓	SCHOR et al., Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: Effect on hyaluronic acid synthesis, In Vitro Cellular Development and Biology, Vol. 25, Number 8, pp. 737-746, August 1989	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Information Disclosure Statement for US 09/581,651

RECEIVED

Cited in International Search Report or Written Opinion

APR 01 2002

TECH CENTER 1600/2900

- #10 1. WO94/16085
- #9 2. WO90/00567
- #13 3. Kornblihtt *et al* (1985) EMBL Sequence Database Accession No X02761
- #13 4. Kornblihtt *et al* (1985) *EMBO J* 4(7), 1755-1759
- #14 5. Kornblihtt *et al* (1986) SWISSPROT Sequence Database Accession No P02751
- #7 6. EP 0 207 751 A
- #15 7. PIRI Sequence Database (1985) Accession Ref FNHU
- #16 8. Dean *et al* (1987) *PNAS USA* 84, 1876-1880
- #8 9. EP 0 344 134 A
- #5 10. US 5,571,679
- #6 11. US 5,629,291
- #17 12. Hynes *et al* (1989) EMBL Data library PIR2 Accession No S14428
- #18 13. Desimone *et al* (1997) SWISSPROT Database Accession Ref FINC_XENLA

Other documents

- #21 14. Schor *et al* (1993) in *Cell behaviour: Adhesion and Motility* (ed G. Evans, C. Wigley & R. Warn) Society for Experimental Biology Symposium No 47, pp 235-251
- #19 15. Schor (1995) in *Epithelial-Mesenchymal Interactions in Cancer*, Ed Foldberg & Rosen, pp 273-296
- #7 16. Grey *et al* (1989) *PNAS USA* 86, 2438-2442

- #23 ✓ 17. Schor *et al* (1994) in Mammary Tumorigenesis and Malignant Progression, Ed Dickson & Lippman, pp 277-298
- #23 18. Irwin *et al* (1994) *J Cell Sci* **107**, 1333-1346
- #24 19. Schor *et al* (1994) *Int J Cancer* **59**, 25-32
- #25 20. Picardo *et al* (1991) *Lancet* **337**, 130-133
- #26 21. Ellis *et al* (1992) *J Cell Sci* **102**, 447-456
- #27 22. Picardo *et al* (1992) *Exp Mol Pathol* **57**, 8-21
- #28 23. Schor *et al* (1991) in Cell Motility Factors, Ed Goldberg pp127-146
- #29 24. Schor *et al* (1988) *J Cell Sci* **90**, 401-407
- #30 25. Schor *et al* (1988) *J Cell Sci* **90**, 391-399
- #31 26. Schor & Schor (1991) *Cancer Invest* **8(6)**, 665-667
- #32 ✓ 27. Schor *et al* (1989) *In Vitro* **25**, 737-746
- #4 28. US 5,300,630
- #1 29. US 4,980,279
- #✓ 30. US 5,049,658.
- #3 31. US 5,124,155
- #11 32. WO99/02674.